Mucormycosis in the COVID-19 Environment: A Multifaceted Complication

Area of Science:

• Infectious Diseases
• Mycology
• Public Health

Background:

• The second wave of coronavirus disease 2019 (COVID-19) was associated with severe infections and high mortality.
• A significant increase in COVID-19-associated mucormycosis (CAM) cases was observed, particularly in India.
• Mucormycosis is a life-threatening fungal infection, especially in immunocompromised individuals.

Purpose of the Study:

• To review the diagnosis, management, and drug discovery advancements for mucormycosis.
• To summarize the major factors influencing mucormycosis occurrence in COVID-19 patients.
• To explore the molecular mechanisms and predisposing factors of CAM.

Main Methods:

• Analysis of published literature and case reports on COVID-19-associated mucormycosis.
• Review of diagnostic and management strategies for mucormycosis.
• Examination of molecular mechanisms, including iron metabolism, in CAM.

Main Results:

• Key predisposing factors for mucormycosis include uncontrolled diabetes, steroid therapy, and certain cancers.
• Elevated iron levels in COVID-19 patients may contribute to the development of mucormycosis.
• High diabetes prevalence and fungal spore burden in India are also discussed as contributing factors.

Conclusions:

• Understanding the confounding factors and molecular mechanisms of CAM is crucial for effective management.
• Iron metabolism regulation in COVID-19 patients warrants further investigation for its role in fungal growth.
• Multifactorial approaches are needed to address the rise of mucormycosis in the context of COVID-19.